New drug duo aims to tackle tough lung cancer
Disease control
Recruiting now
This phase 2 trial tests a new drug called ILKN421H combined with the immunotherapy pembrolizumab in 80 people with advanced non-small cell lung cancer. The study includes patients who have already tried other treatments or are newly diagnosed with a specific biomarker. Researche…
Phase: PHASE2 • Sponsor: iLeukon Therapeutics, Inc. • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC